To evaluate the effect of PKP2 gene therapy in the setting of existing ARVC, PKP2 Hom mice were injected with AAV at 5 × 1011 genome copies per mouse at 4 weeks of age (Fig. 8a), a time point at which all gross ARVC disease features are present (Figs. 1 and 2). This evidence concerns the gene PKP2 and Arrhythmogenic right ventricular dysplasia.